Abstract
In the last few decades, glucocorticoids have received increasing attention for their capability of provoking systemic hypersensitivity reactions, when administered orally, parenterally, or intralesionally, as well as allergic skin and mucosal symptoms, when applied locally to the skin in patients with contact dermatitis or to the mucosa in patients with asthma and/or rhinitis. However, because of their anti-inflammatory and immunosuppressive properties, glucocorticoids are often not suspected of such hypersensitivity reactions. In addition, because glucocorticoids retain their antiinflammatory potential, even if they act as sensitizers, the signs and symptoms of allergic reactions are not always obvious, particularly when they overlap with those caused by the very diseases glucocorticoids are used to treat. Moreover, interpretation of diagnostic tests, specifically that of patch-test reactions, can be difficult. In this review, particular attention is addressed to the problem of allergenic cross-reactivity among topical and systemic glucocorticoids. We also look at the clinical and practical aspects of both cell-mediated and IgE-mediated hypersensitivity reactions to glucocorticoids and their consequences on anti-inflammatory therapeutic choices.
Keywords: Adverse drug reaction, Contact dermatitis, Cell-mediated-reaction, Cross-reactivity, Glucocorticosteroids, Hypersensitivity, IgE-mediated-reaction, Intradermal tests, Patch tests
Current Pharmaceutical Design
Title: Cross-Reactivity in Cell-Mediated and IgE-Mediated Hypersensitivity to Glucocorticoids
Volume: 12 Issue: 26
Author(s): M. T. Ventura, G. F. Calogiuri, L. Muratore, E. Di Leo, R. Buquicchio, A. Ferrannini, O. Resta and A. Romano
Affiliation:
Keywords: Adverse drug reaction, Contact dermatitis, Cell-mediated-reaction, Cross-reactivity, Glucocorticosteroids, Hypersensitivity, IgE-mediated-reaction, Intradermal tests, Patch tests
Abstract: In the last few decades, glucocorticoids have received increasing attention for their capability of provoking systemic hypersensitivity reactions, when administered orally, parenterally, or intralesionally, as well as allergic skin and mucosal symptoms, when applied locally to the skin in patients with contact dermatitis or to the mucosa in patients with asthma and/or rhinitis. However, because of their anti-inflammatory and immunosuppressive properties, glucocorticoids are often not suspected of such hypersensitivity reactions. In addition, because glucocorticoids retain their antiinflammatory potential, even if they act as sensitizers, the signs and symptoms of allergic reactions are not always obvious, particularly when they overlap with those caused by the very diseases glucocorticoids are used to treat. Moreover, interpretation of diagnostic tests, specifically that of patch-test reactions, can be difficult. In this review, particular attention is addressed to the problem of allergenic cross-reactivity among topical and systemic glucocorticoids. We also look at the clinical and practical aspects of both cell-mediated and IgE-mediated hypersensitivity reactions to glucocorticoids and their consequences on anti-inflammatory therapeutic choices.
Export Options
About this article
Cite this article as:
Ventura T. M., Calogiuri F. G., Muratore L., Di Leo E., Buquicchio R., Ferrannini A., Resta O. and Romano A., Cross-Reactivity in Cell-Mediated and IgE-Mediated Hypersensitivity to Glucocorticoids, Current Pharmaceutical Design 2006; 12 (26) . https://dx.doi.org/10.2174/138161206778194006
DOI https://dx.doi.org/10.2174/138161206778194006 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Electrohydrodynamic Preparation of Nanomedicines
Current Topics in Medicinal Chemistry Thyroid Diseases During Pregnancy: Bibliometric Analysis of Scientific Publications
Endocrine, Metabolic & Immune Disorders - Drug Targets Th17 Cells: The Role in Immunity
Current Immunology Reviews (Discontinued) A Comprehensive Review on Preclinical Evidence-based Neuroprotective Potential of <i>Bacopa monnieri</i> against Parkinson's Disease
Current Drug Targets New Strategies in Drug Development Focusing on the Anti-Protease- Protease Balance in Alpha-1 Antitrypsin Deficiency
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry From the Design to the Clinical Application of Thromboxane Modulators
Current Pharmaceutical Design Natural Proteinaceous Inhibitors of Serine Proteases
Current Pharmaceutical Design Editorial (Thematic Issue: Vitamin D and Vitamin D Receptor in Asthma and Allergy)
Mini-Reviews in Medicinal Chemistry Headache: One of the Most Common and Troublesome Adverse Reactions to Drugs
Current Drug Safety Regulation of the Unfolded Protein Response in Disease: Cellular Stress and microRNAs
Current Immunology Reviews (Discontinued) Patent Annotations
Recent Patents on Anti-Infective Drug Discovery Recent Patents on Influenza Vaccines
Recent Patents on Biotechnology Preclinical Studies and Clinical Trials with Mesenchymal Stem Cell for Demyelinating Diseases: A Systematic Review
Current Stem Cell Research & Therapy Burner Development for the Reduction of NOx Emissions from Coal Fired Electric Utilities
Recent Patents on Mechanical Engineering Association between Gasdermin A, Gasdermin B Polymorphisms and Allergic Rhinitis Amongst Jordanians
Endocrine, Metabolic & Immune Disorders - Drug Targets Room Temperature Metal-Free Synthesis of Aryl/Heteroaryl-Substituted Bis(6-aminouracil-5-yl)methanes Using Sulfamic Acid (NH2SO3H) as an Efficient and Eco-friendly Organo-Catalyst
Current Organocatalysis HIF-1α Deficiency Perturbs T and B Cell Functions
Current Pharmaceutical Design Recent Developments on Endothelin Antagonists as Immunomodulatory Drugs - from Infection to Transplantation Medicine
Recent Patents on Cardiovascular Drug Discovery Serum MicroRNA-21 as a Biomarker for Allergic Inflammatory Disease in Children
MicroRNA Type 1 11 β-hydroxysteroid Dehydrogenase as Universal Drug Target in Metabolic Diseases?
Endocrine, Metabolic & Immune Disorders - Drug Targets